Jy. Chang et al., Unique biochemical, cytotoxic, and antitumor activity of camptothecin and 4 beta-amino-4'-O-demethylepipodophyllotoxin conjugates, BIOCH PHARM, 59(5), 2000, pp. 497-508
Two compounds having a camptothecin(CPT) analog conjugated to the 4 beta-am
ino-4'-O demethylepipodophyllotoxin analog were evaluated for their:biochem
ical and biological activities. W1 [camptothecin-(para)-4 beta-amino-4'-O-d
emethylepipodoyhyllotoxin] had no activity against topoisomerase II (TOP II
), but inhibited topoisomerase I (TOP I) with an IC50 value 2-fold higher t
han CPT. W2 [camptothecin-(ortho) -4 beta-amino-4'-O-demethylepipodophyllot
oxin] had inhibitory activity against TOP I and TOP II with Ic,, values 1.5
-fold higher than either CPT or etoposide (VP-16). Both conjugates had simi
lar cptotoxicity against the KB cell line, although the protein-linked DNA
breaks (PLDBs) generated by W2 in KB cells were about 4-fold more than thos
e of W1. No cross-resistance with the two conjugates was seen in a VP-16-re
sistant KB subline, which showed down-regulation of TOP II and overexpressi
on of the multiple drug resistance-associated protein, or in a vincristine-
resistant KB subline with overexpression of gp-170/mdr-1. The CIT-resistant
KB variant (KB CPT 100), which has a reduction in TOP I content and anothe
r mechanism that occurs post-PLDB formation, was partially resistant to bot
h compounds. W1 was nor, affected by this post-PLDB resistance mechanism. C
ell cycle analysis demonstrated that W1 and W2 had similar cell cycle effec
ts on KB and KB CPT 100 cells, which accumulated in S-phase upon drug treat
ment. These results suggested that W1 and W2 exerted their cytotoxicity thr
ough TOP I. In CPT-resistant cells, however, an unidentified target also ma
y be involved in the cytotoxic action of W1, and TOP II may still be a targ
et for W2. In vivo, W1 was more effective against the growth of human prost
ate cancer cells in nude mice than VP-16, CPT, or W2. Given its antitumor a
ctivity and unique biochemical mechanism of action, W1 warrants exploration
as an antitumor compound. (C) 2000 Elsevier Science Inc.